Channing Capital Management LLC lifted its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 0.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 165,561 shares of the company’s stock after purchasing an additional 52 shares during the quarter. Channing Capital Management LLC owned approximately 0.54% of Medpace worth $50,749,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in MEDP. RiverPark Advisors LLC purchased a new position in shares of Medpace during the fourth quarter worth about $26,000. Contravisory Investment Management Inc. acquired a new position in shares of Medpace in the fourth quarter valued at approximately $26,000. FinTrust Capital Advisors LLC purchased a new stake in shares of Medpace during the third quarter worth approximately $30,000. GAMMA Investing LLC purchased a new stake in shares of Medpace during the fourth quarter worth approximately $30,000. Finally, McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Medpace during the fourth quarter worth $33,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.
Medpace Stock Performance
MEDP traded up $1.50 on Friday, hitting $392.57. 133,312 shares of the company were exchanged, compared to its average volume of 261,284. Medpace Holdings, Inc. has a fifty-two week low of $197.39 and a fifty-two week high of $421.00. The firm has a market capitalization of $12.16 billion, a P/E ratio of 40.02, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40. The business’s fifty day moving average is $398.08 and its 200 day moving average is $331.78.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on the stock. Guggenheim upped their price objective on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and increased their price target for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 target price for the company. Finally, Robert W. Baird raised their price target on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $443.00.
Get Our Latest Report on Medpace
Insider Activity
In related news, major shareholder Medpace Investors, Llc sold 50,000 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $391.75, for a total value of $19,587,500.00. Following the sale, the insider now directly owns 5,539,947 shares in the company, valued at approximately $2,170,274,237.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Medpace news, CEO August J. Troendle sold 100,000 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the sale, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the firm’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the transaction, the insider now directly owns 5,539,947 shares of the company’s stock, valued at approximately $2,170,274,237.25. The disclosure for this sale can be found here. Insiders sold a total of 204,442 shares of company stock worth $82,702,867 over the last 90 days. 20.30% of the stock is currently owned by corporate insiders.
About Medpace
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Recommended Stories
- Five stocks we like better than Medpace
- Investing In Preferred Stock vs. Common Stock
- MarketBeat Week in Review – 4/29 – 5/3
- Business Services Stocks Investing
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- What is a buyback in stocks? A comprehensive guide for investors
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.